Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: A comparison with clozapine and placebo

Neuropsychopharmacology

Volumn 27, Issue 2, 2002, Pages 293-300

  Elman, Igor ^a,c   Goldstein, David S ^d   Green, Alan I ^b,c   Eisenhofer, Graeme ^d   Folio, Carol J ^d   Holmes, Courtney S ^d   Pickar, David ^e   Breier, Alan ^f,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Commonwealth Research Center ^*  (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e Univ S Carolina Sch Med Vice P   (United States)

^f ELI LILLY AND COMPANY   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Catecholamine; Clearance; DHPG; Schizophrenia; Spillover; Tritium labeled norepinephrine

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ADRENERGIC RECEPTOR; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOL DERIVATIVE; CLOZAPINE; NORADRENALIN; NORADRENALIN DERIVATIVE; PLACEBO; RISPERIDONE;

ADRENERGIC RECEPTOR BLOCKING; ADULT; ARTERIAL BLOOD; ARTICLE; CATECHOLAMINE BLOOD LEVEL; CATECHOLAMINE METABOLISM; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; HORMONE TRANSPORT; HUMAN; MALE; METABOLITE; NORADRENALIN BLOOD LEVEL; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; CLOZAPINE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEURAL INHIBITION; NOREPINEPHRINE; PERIPHERAL NERVOUS SYSTEM; PLACEBOS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; RISPERIDONE; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SYMPATHETIC FIBERS, POSTGANGLIONIC; SYNAPTIC TRANSMISSION; VASODILATION;

EID: 0036294116     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(02)00314-7     Document Type: Article

References (63)

1. Clozapine-pharmacokinetic investigations and biochemical effects in man
2. Clozapine and noradrenergic function: Support for a novel hypothesis for superior efficacy
3. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia
4. The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy
5. Norepinephrine and schizophrenia: A new hypothesis for antipsychotic drug action
6. Plasma norepinephrine in chronic schizophrenia
7. Clozapine and risperidone in chronic schizophrenia: Effects on symptoms, parkinsonian side effects, and neuroendocrine response
8. Effects of clozapine on plasma catecholamines and relation to treatment response in schizophrenia: A within-subject comparison with haloperidol
9. The use of atypical antipsychotics in the management of schizophrenia
10. Norepinephrine removal and release in the forearm of healthy subjects
11. Diabetic ketoacidosis associated with clozapine treatment
12. Diabetic ketoacidosis associated with risperidone treatment?
13. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia
14. Neuronal re-uptake of noradrenaline by sympathetic nerves in humans
15. Cardiac sympathetic nerve function in congestive heart failure
16. Simultaneous liquid-chromatographic determination of 3,4- dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase
17. Mechanism of peripheral noradrenergic stimulation by clozapine
18. Determination of norepinephrine apparent release rate and clearance in humans
19. Effect of norepinephrine uptake blockers on norepinephrine kinetics
20. Overflow of catecholamine neurotransmitters to the circulation: Source, fate, and functions
21. Central and peripheral norepinephrine kinetics in heart failure, coronary artery disease, and hypertension
22. Biogenic amines as predictors of response to clozapine treatment in early-onset schizophrenia
23. Measurements of plasma norepinephrine concentrations in human primary hypertension. A word of caution on their applicability for assessing neurogenic contributions
24. The role of norepinephrine in the pathophysiology of cognitive disorders: Potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease
25. Pharmacologic strategies for augmenting cognitive performance in schizophrenia
26. Negative symptoms in schizophrenia: Neurobiological models and treatment response
27. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans
28. Neuronal source of plasma dihydroxyphenylalanine
29. Clozapine response and plasma catecholamines and their metabolites
30. Metabolic fate of injected radiolabelled dopamine and 2-fluorodopamine in rats
31. Catecholamine uptake processes
32. Plasma MHPG in rapid cyclers and healthy twins
33. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine
34. Treatment of schizophrenia
35. Brain noradrenergic receptors in major depression and schizophrenia
36. Cerebral noradrenaline spillover and its relation to muscle sympathetic nervous activity in healthy human subjects
37. Determination of metanephrines in plasma by liquid chromatography with electrochemical detection
38. Value of the plasma norepinephrine/3,4-dihydroxyphenylglycol ratio for the diagnosis of pheochromocytoma
39. Biochemical profile of risperidone, a new antipsychotic
40. Clozapine pharmacology and tardive dyskinesia
41. Biochemical effects of clozapine in cerebrospinal fluid of patients with schizophrenia: Advances in neuropsychiatry and psychopharmacology
42. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine
43. Clozapine: Is another view valid?
44. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment
45. Suppressive effect of vasopressin on the hyperglycemic response to intracranial injection of 2-deoxy-D-glucose
46. Effects of chronic risperidone on central noradrenergic transmission
47. Prospects for pharmacotherapy of schizophrenia
48. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine
49. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologic treatment. A review
50. Receptor pharmacology of neuroleptics: Relation to clinical effects
51. Occupancy of central neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by quantitative autoradiography
52. Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adults with schizophrenia
53. Blood biogenic amines during clozapine treatment of early-onset schizophrenia
54. Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia
55. Possible etiology of schizophrenia: Progressive damage to the noradrenergic reward system by 6-hydroxydopamine
56. Biologic tests in psychiatry
57. Alpha2-adrenoceptor-mediated restraint of norepinephrine synthesis, release, and turnover during immobilization in rats
58. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes
59. Possible noradrenergic dysfunction in schizophrenia
60. Inhibitory effects of clozapine and other antipsychotic drugs on noradrenaline transporter in cultured bovine adrenal medullary cells
61. Relationship between norepinephrine in blood and cerebrospinal fluid in the presence of a blood-cerebrospinal fluid barrier for norepinephrine